Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

East meets west: can adding chinese herbs boost weight loss drugs?

NCT ID NCT07646457

Disease control Sponsor: National Yang Ming Chiao Tung University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding Traditional Chinese Medicine (TCM) to standard weight-loss drugs helps people lose more weight. About 296 adults with obesity (BMI 27 or higher) in Taiwan are being followed for 6 to 12 months. Researchers are measuring weight loss, body fat, and muscle-to-fat ratio to see if the combination works better than drugs alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

296 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with overweight or obesity receiving weight management treatment in a hospital-based outpatient setting in Taiwan. Participants were identified from a retrospective clinical database and received pharmacologic therapy, primarily semaglutide, with or without adjunctive medications and/or traditional Chinese medicine interventions.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥20 years * Obesity defined by Health Promotion Administration, Taiwan: BMI ≥27 kg/m², or BMI ≥24 kg/m² with metabolic comorbidities * Received weight management treatment * Primary pharmacologic therapy with: Rybelsus® (oral semaglutide), or Ozempic® (subcutaneous semaglutide) * May have received adjunctive weight-loss medications, including: Mounjaro® (tirzepatide), SGLT2 inhibitors, Contrave® (naltrexone/bupropion) Exclusion Criteria: * Incomplete data, including missing baseline measurements or absence of follow-up records, precluding assessment of treatment effectiveness * Pregnancy or breastfeeding * History of bariatric surgery during the study period (e.g., gastric bypass, gastric banding) * Presence of major medical conditions that may significantly affect body weight independent of obesity treatment (e.g., active malignancy, end-stage organ failure) * Patients deemed unsuitable for inclusion by the investigators (e.g., poor treatment adherence or unreliable data)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

Contacts and locations

Locations

  • National Yang Ming Chiao Tung University

    Taipei, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.